This replica of the body's blood factory is made entirely with human cells. Breakthroughs, discoveries, and DIY tips sent every weekday. Without even thinking about it, the bone marrow in your body is churning out billions of cells every single day. Bone marrow is our body's strong and silent "blood factory," working hard in the background while heart pumps and brain controls. The spongy marrow really gets attention during a blood cancer diagnosis or when this crucial system stops working properly.

Artificial intelligence (AI) and machine learning allow researchers to study databases that otherwise would be too large and complex. In a recent study, Sloan Kettering Institute computational biologist Quaid Morris and collaborators used models to study an aging-related blood condition called clonal hematopoiesis (CH). Their research showed how evolution and natural selection influence CH and the effects that it may have on health outcomes. CH is relatively common in older people, affecting up to 10% of the population by age 80. The condition raises the risk of developing blood disorders -- including some blood cancers -- and cardiovascular disease. "One of the issues that we face in studying something complicated like CH is the interplay of many different factors," says Dr. Morris, who is co-senior author of a paper on CH published August 13, 2021, in Nature Communications.

Washington: Tracking down acute myeloid leukaemia (AML), researchers have proved that artificial intelligence can detect forms of blood cancer. The study was conducted by the researchers of the German Center for Neurodegenerative Diseases (DZNE) and was published in the recent edition of the iScience journal. The approach used by researchers revolved around the gene activity analysis of cells that are present in the blood. This approach could support conventional diagnostics and accelerate therapy of the disease. "Some studies have been carried out on this topic and the results are available through. Thus, there is an enormous data pool. We have collected virtually everything that is currently available," said Professor Joachim Schultze who led the group of researchers of the study.

Sophia Genetics has received a CE-IVD mark for its molecular diagnostics test, which will improve the detection of leukemia. Swiss company Sophia Genetics is a leader in the field of data-driven medicine, with its artificial intelligence (AI) technology already been used to analyze the next-generation sequencing data of over 160,000 patients' around the world. Today, the company has received a CE-IVD mark for its molecular diagnostics tool, meaning it can be traded within the European single market. The technology reads the genome more precisely to improve the diagnosis of leukemia and boost the personalization of cancer care. By receiving a CE mark, the company now has permission to trade its product within the European single market as it has shown no adverse effects on human health or the environment.